Le Lézard
Classified in: Health
Subjects: PDT, FDA

Novadoz Pharmaceuticals/MSN Labs gains FDA approval and commences shipping of Pregabalin capsules, the largest generic product launch of the year

PISCATAWAY, N.J., July 23, 2019 /PRNewswire/ -- Novadoz Pharmaceuticals, the U.S based sales & marketing affiliate for MSN Labs, based in Hyderabad India, has received FDA approval for their generic version of Pregabalin capsules on July 19th.  The patent expiration for the brand Lyrica© marketed by Pfizer, occurred on that day which cleared the way for the company to begin immediate shipping of the product.   


Novadoz Pregabalin capsules are available in 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, and 300mg strength capsules in 90 count bottles, with bulk sizes slated for post launch. Pregabalin is indicated for epilepsyneuropathic painfibromyalgia, and restless leg syndrome. Its use to treat epilepsy as adjunctive therapy for partial seizures. The brand is currently trending over $5.4 BIL USD in published annual sales.   

Seshu Akula, Novadoz President North America Generics, was quoted, "The approval for Pregabalin, one of the largest generic industry launches in past several years, was a tremendous accomplishment for our entire organization.  This product will be an important one for Novadoz over the next decade, providing a steady revenue stream while defining our company's ability to be a consistent and reliable supplier to our customers.  We are anticipating an additional 10 to 12 product launches over the next 18 months, that continues the bright outlook we have on our future in the U.S market."

Novadoz's, Tom DeStefano, Vice President Sales & Marketing states, "Novadoz's entrance as a DAY 1 supplier of Pregabalin, further elevates our company's status as a generic supplier.  The scope and size of the product requires a highly efficient and well-planned supply chain and manufacturing process.  MSN brings this level of competency to this launch, as well as supporting our current business and future product introductions."

MSN Labs is engaged in the development and manufacturing of API (active pharmaceutical ingredients), KSMs (key starting materials), and product intermediates.  MSN is recognized as a global leader in this category.  In addition, the company manufactures finished dosage oral solids, liquids, and injectable products in sixty-five markets throughout the world, doing business in the U.S under the Novadoz label.

For more information, visit the company's websites at www.NovadozPharma.comwww.MSNLabs.com

Tom DeStefano
Novadoz Pharmaceuticals
Vice President Sales and Marketing
(908) 360-1500, ext. 507

SOURCE Novadoz Pharmaceuticals

These press releases may also interest you

at 10:41
The Department of Transportation invited FlyersRights.org and other consumer organizations to a conference call Tuesday to discuss the DOT's coronavirus response. FlyersRights.org strongly criticized the joint Departments of Transportation (DOT),...

at 10:30
According to the new market research report "Teleradiology Market by Products & Services (Services, Hardware, Software (PACS, RIS)), Imaging Technique (MRI, CT, X-ray, Ultrasound, Mammography, Nuclear Imaging), End User (Hospitals, Diagnostic Centers...

at 10:30
ProMach, a worldwide leader in packaging machinery solutions, announced today that it has acquired Modern Packaging, a leading manufacturer of filling and sealing solutions for the food and dairy industries. The addition of Modern expands ProMach's...

at 10:29
Dignitana AB today announces a partnership with Nuffield Health in the United Kingdom to provide DigniCap scalp cooling to minimize hair loss from chemotherapy. As the largest healthcare charity in the United Kingdom, Nuffield Health operates 31...

at 10:15
MJH Life Sciencestm today announced it has acquired Pharmaceutical Commerce®, a multimedia platform published by Healthcare Commerce Media Corporation. This latest addition to the MJH portfolio strengthens the position of MJH Life Sciencestm in the...

at 10:13
OtoNexus Medical Technologies Inc., announced today that Keiretsu Capital has invested in OtoNexus for the fourth time. Keiretsu Capital and Keiretsu Forum members are leading investors in OtoNexus with a total of $13 million in funding since the...

News published on 23 july 2019 at 13:29 and distributed by: